NO20000007L - Anvendelse av veksthormon i sammensetninger til behandling av insulinresistens i hjertet samt for å øke protein-kinase-B(PKB)- aktivitet - Google Patents

Anvendelse av veksthormon i sammensetninger til behandling av insulinresistens i hjertet samt for å øke protein-kinase-B(PKB)- aktivitet

Info

Publication number
NO20000007L
NO20000007L NO20000007A NO20000007A NO20000007L NO 20000007 L NO20000007 L NO 20000007L NO 20000007 A NO20000007 A NO 20000007A NO 20000007 A NO20000007 A NO 20000007A NO 20000007 L NO20000007 L NO 20000007L
Authority
NO
Norway
Prior art keywords
heart
growth hormone
insulin resistance
pkb
compositions
Prior art date
Application number
NO20000007A
Other languages
English (en)
Norwegian (no)
Other versions
NO20000007D0 (no
Inventor
Thomas Olin
Christina Reuterdahl
Axel Stohlbom
Antek Wielburski
Harriet Roennholm
Stephen James
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9702595A external-priority patent/SE9702595D0/xx
Priority claimed from SE9802023A external-priority patent/SE9802023D0/xx
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Publication of NO20000007D0 publication Critical patent/NO20000007D0/no
Publication of NO20000007L publication Critical patent/NO20000007L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
NO20000007A 1997-07-04 2000-01-03 Anvendelse av veksthormon i sammensetninger til behandling av insulinresistens i hjertet samt for å øke protein-kinase-B(PKB)- aktivitet NO20000007L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9702595A SE9702595D0 (sv) 1997-07-04 1997-07-04 new therapeutic use
SE9802023A SE9802023D0 (sv) 1998-06-08 1998-06-08 New therapeutic use
PCT/SE1998/001261 WO1999001151A1 (en) 1997-07-04 1998-06-26 Use of growth hormone in compositions for treating insulin resistance in the heart and for enhancing protein kinase b (pkb) activity

Publications (2)

Publication Number Publication Date
NO20000007D0 NO20000007D0 (no) 2000-01-03
NO20000007L true NO20000007L (no) 2000-03-06

Family

ID=26663028

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20000007A NO20000007L (no) 1997-07-04 2000-01-03 Anvendelse av veksthormon i sammensetninger til behandling av insulinresistens i hjertet samt for å øke protein-kinase-B(PKB)- aktivitet

Country Status (12)

Country Link
EP (1) EP1007085B1 (pt)
JP (1) JP2002511876A (pt)
AT (1) ATE209042T1 (pt)
AU (1) AU737065B2 (pt)
CA (1) CA2294824A1 (pt)
DE (1) DE69803298T2 (pt)
DK (1) DK1007085T3 (pt)
ES (1) ES2168772T3 (pt)
NO (1) NO20000007L (pt)
NZ (1) NZ501961A (pt)
PT (1) PT1007085E (pt)
WO (1) WO1999001151A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4669499A (en) * 1998-06-08 1999-12-30 Pharmacia & Upjohn Ab New therapeutic use of pkb (proteine kinase b) enhancers
SE9901634D0 (sv) * 1999-05-05 1999-05-05 Sahltech Ab Treatment of myocardial infarction with a substance related to the growth hormone axis
AU2006200127B2 (en) * 2000-03-13 2007-10-25 Pfizer Inc. Use of growth hormone in low dose
SE0000837D0 (sv) 2000-03-13 2000-03-13 Pharmacia & Upjohn Ab New use
AU2007289344B2 (en) * 2006-08-31 2011-04-14 Novartis Ag Pharmaceutical compositions comprising hGH for oral delivery

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935924A (en) * 1994-04-15 1999-08-10 Genentech, Inc. Treatment of congestive heart failure
WO1995028713A1 (fr) * 1994-04-18 1995-10-26 Gay Freres Vente Et Exportation S.A. Dispositif a memoire electronique
EP0766966A3 (en) * 1995-09-08 2001-02-28 Eli Lilly And Company Method of treating insulin resistance
SE9601397D0 (sv) * 1996-04-12 1996-04-12 Pharmacia Ab Use of growth hormone

Also Published As

Publication number Publication date
DE69803298T2 (de) 2002-08-08
JP2002511876A (ja) 2002-04-16
DK1007085T3 (da) 2002-05-13
EP1007085A1 (en) 2000-06-14
WO1999001151A1 (en) 1999-01-14
PT1007085E (pt) 2002-05-31
NZ501961A (en) 2001-11-30
AU737065B2 (en) 2001-08-09
ATE209042T1 (de) 2001-12-15
DE69803298D1 (de) 2002-02-21
AU8250698A (en) 1999-01-25
NO20000007D0 (no) 2000-01-03
ES2168772T3 (es) 2002-06-16
EP1007085B1 (en) 2001-11-21
CA2294824A1 (en) 1999-01-14

Similar Documents

Publication Publication Date Title
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
ATE301459T1 (de) Norbornen- und norbornandiolen zur behandlung von pigmentierungsstörungen, neurodegenerativen erkrankungen oder proliferativen hauterkrankungen
ATE285219T1 (de) Rekombinante haarbehandlungsmittel
ATE347366T1 (de) Verwendung von activem vitamin d analoga zur behandlung von prostataerkrangkungen
ATE199643T1 (de) Therapeutisches kombinationspräparat enthaltend interferon
DE1019040T1 (de) Hemmung von p38 kinase aktivität durch arylharnstoff
CA2068324A1 (en) Metal-peptide compositions and methods for stimulating hair growth
DE69731540D1 (de) Behandlung von diarrhoe
ES2010561A6 (es) Procedimiento para preparar una composicion farmaceutica a base de un analogo de somatostatina.
WO2001030802A3 (en) Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies
CA2245766A1 (en) Compositions useful in the phototherapeutic treatment of proliferative skin disorders
EE9900428A (et) Köhavastased ravimkoostised
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
NO994330L (no) Metode for behandling av en tumor
HUT66309A (en) Bpc peptides, their preparation and therapeutic use
GB8805792D0 (en) Medicaments
CA2156481A1 (en) 5-ht2 receptor antagonist compositions useful in treating venous conditions
NO20000007D0 (no) Anvendelse av veksthormon i sammensetninger til behandling av insulinresistens i hjertet samt for å oeke proteinkinase-B(PKB)- aktivitet
ATE297739T1 (de) Endothelin-antagonisten zur behandlung von herzversagen
DE60028559D1 (de) Behandlung von multiplersklerose mit einer kombination von interferon und wachstumshormone
DE69623316D1 (de) Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen
HUP0300923A2 (hu) RAF és RAS protein kinázt tartalmazó készítmények és alkalmazásuk angiogenezis módosítására
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
WO1999013894A3 (en) Use of ifn-alpha and amantadine for the treatment of chronic hepatitis c
ATE88090T1 (de) Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application